Monitoring drug resistance in leishmaniasis

Tropical Medicine and International Health

Volumn 6, Issue 11, 2001, Pages 899-905

  Croft, Simon L ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Antimonials; Drug resistance; Leishmaniasis; Species variation

Indexed keywords

ALLOPURINOL; ALLOPURINOL RIBOSIDE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; ITRACONAZOLE; KETOCONAZOLE; MEGLUMINE ANTIMONATE; MILTEFOSINE; NUCLEOSIDE DERIVATIVE; PAROMOMYCIN; PENTAMIDINE; PYRROLE; SITAMAQUINE; STIBOGLUCONATE SODIUM; TERBINAFINE;

DISEASE TREATMENT; DRUG RESISTANCE; LEISHMANIASIS; MONITORING;

AMASTIGOTE; ANTIBIOTIC RESISTANCE; CELLULAR IMMUNITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG SENSITIVITY; HUMAN; IMMUNE STATUS; IN VITRO STUDY; LEISHMANIA DONOVANI; LEISHMANIASIS; MACROPHAGE; NONHUMAN; PROMASTIGOTE; REVIEW; SPECIES DIFFERENCE;

ANIMALS; ANTIPROTOZOAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; HUMANS; IMMUNOCOMPETENCE; LEISHMANIA; LEISHMANIASIS; PARASITIC SENSITIVITY TESTS; SPECIES SPECIFICITY; VARIATION (GENETICS);

LEISHMANIA DONOVANI; PROTOZOA;

EID: 0034771454     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3156.2001.00754.x     Document Type: Review

References (57)

1. Pharmacokinetics of antimony in patients treated with sodium stibogluconate for cutaneous leishmaniasis
2. The in vitro susceptibility of macrophages infected with amastigotes of Leishmania spp. to pentavalent antimonial drugs and other compounds with special relevance to cutaneous isolates
3. Leishmania and human immunodeficiency virus coinfection: The first 10 years
4. Involvement of thiol metabolism in resistance to Glucantime in Leishmania tropica
5. A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran
6. Comparative effects of 4-aminopyrazolopyrimidine, its 2′-deoxyriboside derivative, and allopurinol on in vitro growth of American Leishmania species
7. Altered transport properties of pentamidine-resistant Leishmania donovani and Leishmania amazonensis promastigotes
8. Effects of antimycotic azoles on growth and sterol biosynthesis of Leishmania promastigotes
9. In vitro susceptibility of antimony-resistant Leishmania to alternative drugs
10. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries
11. Susceptibility of clinical sensitive and resistant leishmania in vitro
12. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance
13. Isolation of genes mediating resistance to inhibitors of nucleoside and ergosterol metabolism in Leishmania by overexpression/selection
14. In vitro screens in the experimental chemotherapy of leishmaniasis and trypanosomiasis
15. Chemotherapy of human leishmaniasis and trypanosomiasis
16. A revised classification for Leishmania and Endotrypanum
17. Flow cytometric assessment of amphotericin B susceptibility in Leishmania infantum isolates from patients with visceral leishmaniasis
18. Leishmania infantum: Lack of parasite resistance to amphotericin B in a clinically resistant visceral leishmaniasis
19. Topical treatment of old world cutaneous leishmaniasis caused by Leishmania major: A double-blind study
20. Topical treatment of new and old world leishmaniasis in experimental animals
21. Pentostam induces resistance to antimony and the preservative chlorocresol in Leishmania donovani promastigotes and axenically grown amastigotes
22. Drug responsiveness in experimental cutaneous leishmaniasis
23. The activity of hexadecylphosphocholine (miltefosine), AmBisome and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice
24. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: A study of 37 strains collected from patients with visceral leishmaniasis
25. Paromomycin resistance in Leishmania tropica: Lack of correlation with mutation in the small subunit ribosomal RNA gene
26. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment
27. Leishmania spp: Development of Pentostam-resistant clones in vitro by discontinuous drug exposure
28. Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (aminosidine) and gentamicin
29. Drug resistance in leishmaniasis: Its implication in systemic chemotherapy of cutaneous and mucocutaneous disease
30. Amplification of the ABC transporter gene PGPA and increased trypanothione levels in potassium antimonyl tartrate (SbIII) resistant Leishmania tarentolae
31. Leishmania resistant to sodium stibogluc-onate: Drug-associated macrophage-dependent killing
32. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis
33. Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria
34. Pharmacokinetics and pharmacology of terbinafine and itraconazole
35. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania dono-vani
36. Development and characterization of paromomycin-resistant Leishmania donovani promastigotes
37. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes
38. US Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis
39. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms
40. Treatment of experimental visceral leishmaniasis in a T-cell-deficient host: Response to amphotericin B and pentamidine
41. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis
42. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala
43. Experimental chemotherapy
44. The sensitivity of Leishmania species to aminosidine
45. Anti-leishmanial effect of allopurinol ribonucleoside and the related compounds, allo-purinol, thiopurinol, thiopurinol riboside, and of formycin B, sinefungin and the lepidine WR6026
46. Allopurinol ribonucleoside as an antileishmanial agent
47. ABC transporters in Leishmania and their role in drug resistance
48. Naturally azole-resistant Leishmania braziliensis promastigotes are rendered susceptible in the presence of terbinafine: Comparative study with azole-susceptible Leishmania mexicana promastigotes
49. In vitro antileish-manial properties of tri- and pentavalent antimonial preparations
50. Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents
51. Phase 2 efficacy trial of an 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis
52. New approaches to cutaneous leishmaniasis treatment in Latin America
53. Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica
54. Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study
55. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: A study of 938 cases
56. Molecular mechanisms of drug resistance in fungi